The intervening research of Trimetazidine combined with Metoprolol in the treatment of cardiac pacing patients with atrial fibrillation and without asymptomatic atrial fibrillation

CHEN Yang; LIANG Hai-feng; DU Xue-ping

doi:10.3969/j.issn.1672-5301.2017.07.018

Abstract：Objective To investigate the intervening effects of Trimetazidine combined with Metoprolol in the treatment of cardiac pacing patients with atrial fibrillation and without asymptomatic atrial fibrillation. Meth-ods From August 2013 to February 2016, 88 atrial fibrillation patients with implanted dual chamber permanent cardiac pacemaker in our hospital were selected as the research object, all the patients were randomly divided into observation group and control group of 43 patients accorded to the random lottery envelopes. The control group was given Metoprolol therapy after pacemaker implantation for 3 months, the observation group was added given the Trimetazidine therapy based on the control group. Two groups were observed for 3 months. Results All patients were completed the treatment and there were no thrombosis, heart failure, bleeding and death occurred during the treatment. After treatment, there were 6 patients were atrial fibrillation occurred the observation group that included 4 patients of without asymptomatic atrial fibrillation; while the control group were 14 patients of atrial fibrillation that included 3 patients of without asymptomatic atrial fibrillation, the observation group was better in the control group (P<0.05). After treatment, the levels of serum CRP and IL-6 in observation group and control group were (2.19±0.49)mg/L,(87.39±51.43)pg/ml and(4.22±0.99)mg/L,(103.88±41.45)pg/ml that were significantly less than those before treatment (P<0.05), while the serum CRP and IL-6 levels in the observation group after treat-ment were significantly less than those in the control group (P<0.05). The LAEDD and IVST values in the obser-vation group after treatment were(40.67±2.14)mm and(12.11±0.98)mm, while the control group were(43.29± 1.40)mm and (13.78±0.91)mm, the observation group were significantly lower than the control group (P<0.05) and were significantly lower than those before treatment (P<0.05). Conclusion The application of Trimetazidine combined with Metoprolol in the treatment of cardiac pacing patients with atrial fibrillation and without asymptomat-ic atrial fibrillation can inhibit the occurrence of atrial fibrillation, it has significant improvement for atrial remodel-ing, the mechanism may be related to anti inflammation.